Quantcast
Home > Quotes > ATHX
ATHX

Athersys, Inc. Common Stock (ATHX) Quote & Summary Data

$1.32
*  
0.09
7.32%
Get ATHX Alerts
*Delayed - data as of Aug. 16, 2019  -  Find a broker to begin trading ATHX now
Exchange:NASDAQ
Industry: Health Care
Community Rating:
 
 
Symbol List Views
FlashQuotes InfoQuotes
Stock Details
Summary Quote Real-Time Quote After Hours Quote Pre-market Quote Historical Quote Option Chain
CHARTS
Basic Chart Interactive Chart
COMPANY NEWS
Company Headlines Press Releases Market Stream
STOCK ANALYSIS
Analyst Research Guru Analysis Stock Report Competitors Stock Consultant Stock Comparison
FUNDAMENTALS
Call Transcripts Annual Report Income Statement Revenue/EPS SEC Filings Short Interest Dividend History
HOLDINGS
Ownership Summary Institutional Holdings Insiders
(SEC Form 4)
 Save Stocks

Key Stock Data

Best Bid / Ask
N/A / N/A
1 Year Target
Today's High / Low
$ 1.37 / $ 1.25
Share Volume
522,691
50 Day Avg. Daily Volume
595,740
Previous Close
$ 1.23
52 Week High / Low
$ 2.23 / $ 1.20
Market Cap
201,534,631
Annualized Dividend
N/A
Ex Dividend Date
N/A
Dividend Payment Date
N/A
Current Yield
0 %
Beta
1.7

Intraday Chart

Shares Traded

Share Volume:
522,691
50 Day Avg. Daily Volume:
595,740

P/E Ratio

P/E Ratio:
NE
Forward P/E (1y):
Earnings Per Share (EPS):
$ -0.30

Trading Range

The current last sale of $1.32 is 10.00% Higher than the 52 week low.

Intraday Last 52 Weeks
High: $ 1.37 $ 2.23
 Low: $ 1.25 $ 1.20

Company Description (as filed with the SEC)

We are an international biotechnology company that is focused in the field of regenerative medicine. We are committed to the discovery and development of best-in-class therapies designed to extend and enhance the quality of human life and have established a portfolio of therapeutic product development programs to address significant unmet medical needs in multiple disease areas. Our MultiStem┬« cell therapy, a patented and proprietary allogeneic stem cell product, is our lead platform product and is currently in clinical development. Our most advanced program is focused on the treatment of ischemic stroke, which is currently being evaluated in a registrational trial in Japan, and in a Phase 3 clinical trial in North America under a Special Protocol Assessment, or SPA, and Europe.  ... More ...  

Nasdaq Official Price

Open Price:
$ 1.25
Open Date:
Aug. 16, 2019
Close Price:
$ 1.32
Close Date:
Aug. 16, 2019


Research Brokers before you trade

Want to trade FX?

Analyst Info